Method for Discovering Novel Transcriptional Regulators

Information

  • Research Project
  • 6728262
  • ApplicationId
    6728262
  • Core Project Number
    R42GM057712
  • Full Project Number
    5R42GM057712-03
  • Serial Number
    57712
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/1998 - 26 years ago
  • Project End Date
    3/31/2006 - 18 years ago
  • Program Officer Name
    WOLFE, PAUL B.
  • Budget Start Date
    4/1/2004 - 20 years ago
  • Budget End Date
    3/31/2006 - 18 years ago
  • Fiscal Year
    2004
  • Support Year
    3
  • Suffix
  • Award Notice Date
    3/15/2004 - 20 years ago

Method for Discovering Novel Transcriptional Regulators

DESCRIPTION (provided by applicant): Regulation of gene expression by transcription factors is one of the most fundamental biological processes. The pharmaceutical manipulation of this process would open doors toward new approaches to treatment of cancer and other major diseases. We aim to develop a novel, comprehensive technology for manipulation of gene expression based on synthetic analogues of eukaryotic transcription factors. The design and synthesis of these artificial transcription factors (ATFs) has been accomplished in Phase I by replacing functional domains of natural transcription factors with artificial chemical moieties. These ATFs have a remarkably high biological activity combined with novel properties resulting from their unique chemical composition and structure. In Phase II we propose to develop ATF technology further and apply it to target selected human genes in their native, chromosomal setting in tissue culture cells. This will be achieved by using a combination of chemical, biochemical, genetic and genomic tools. The specific aims of this proposal are: 1) Expanding the repertoire of ATFs with new chemical moieties. 2) Developing a robust and rapid assay for testing of ATFs in human cell culture lines. 3) Demonstration of the ability of ATFs to target selected endogenous human genes in tissue culture.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R42
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    348874
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:348874\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CROSSLINK GENETICS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES